论文部分内容阅读
目的:观察东菱对频发性短暂性脑缺血发作的疗效。方法:观察74例病人,随机分为治疗组(38例)和对照组(36例),治疗组给予生理盐水250 ml+东菱克栓酶5iu首次倍量隔天静点1次,33次为1个疗程;对照组给予生理盐水250 ml+盐酸丁咯地尔300mg每天静点1次,7次为1个疗程,两组患者常规给予活血化淤、抗血小板聚集、健脑等药物治疗,7天为1疗程。结果:治疗组与对照组1天内TIA发作控制率分别为68.42%和55.56%;3天内TIA发作控制率分别为97.73%和80.56%;治疗期间治疗组发生脑梗塞为1人占2.63%,对照组为4人占11.11%;两个月内TIA复发率及发展为脑梗塞患者对照组组明显高于治疗组。血液粘度、纤维蛋白原治疗后比较两组有显著差异(P<0.01),但凝血酶原时间无明显变化(P>0.05),治疗组病人均无1例出血。结论:东菱克栓酶治疗频发性短暂性脑缺血发作是行之有效的,安全系数高,值得临床医生进一步推广及研究。
Objective: To observe the effect of DF on the incidence of TIA. Methods: A total of 74 patients were randomly divided into treatment group (38 cases) and control group (36 cases). The treatment group was treated with normal saline 250 ml + 1 treatment; control group given saline 250ml buflomedil hydrochloride 300mg once a day static point, 7 times for a course of treatment, two groups of patients given conventional blood stasis, anti-platelet aggregation, brain and other drugs, 7 Days for a course of treatment. Results: The control rates of TIA in treatment group and control group were 68.42% and 55.56% respectively within one day. The control rates of TIA in three days were 97.73% and 80.56% respectively. The incidence of cerebral infarction in treatment group was 2.63% The group of 4 people accounted for 11.11%; TIA within two months and the development of cerebral infarction patients in the control group was significantly higher than the treatment group. Blood viscosity, fibrinogen after treatment were significantly different between the two groups (P <0.01), but no significant changes in prothrombin time (P> 0.05), no bleeding in the treatment group of patients. Conclusion: Bolltung’s treatment of transient ischemic attacks is effective, with high safety factor, which is worth further promotion and research by clinicians.